Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
AuthorsPlummer, E Ruth
Middleton, Mark R
Margison, Geoffrey P
Thorncroft, Mary R
Watson, Amanda J
Boddy, Alan V
Calvert, A Hilary
Harris, Adrian L
Newell, David R
Curtin, Nicola J
AffiliationNorthern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom. E.R.Plummer@ncl.ac.uk
MetadataShow full item record
AbstractPURPOSE: Temozolomide, a DNA methylating agent used to treat melanoma, induces DNA damage, which is repaired by O6-alkylguanine alkyltransferase (ATase) and poly(ADP-ribose) polymerase-1 (PARP-1)-dependent base excision repair. The current study was done to define the effect of temozolomide on DNA integrity and relevant repair enzymes as a prelude to a phase I trial of the combination of temozolomide with a PARP inhibitor. EXPERIMENTAL DESIGN: Temozolomide (200 mg/m2 oral administration) was given to 12 patients with metastatic malignant melanoma. Peripheral blood lymphocytes (PBL) were analyzed for PARP activity, DNA single-strand breakage, ATase levels, and DNA methylation. PARP activity was also measured in tumor biopsies from 9 of 12 patients and in PBLs from healthy volunteers. RESULTS: Temozolomide pharmacokinetics were consistent with previous reports. Temozolomide therapy caused a substantial and sustained elevation of N7-methylguanine levels, a modest and sustained reduction in ATase activity, and a modest and transient increase in DNA strand breaks and PARP activity in PBLs. PARP-1 activity in tumor homogenates was variable (828 +/- 599 pmol PAR monomer/mg protein) and was not consistently affected by temozolomide treatment. CONCLUSIONS: The effect of temozolomide reported here are consistent with those documented in previous studies with temozolomide and similar drug, dacarbazine, demonstrating that a representative patient population was investigated. Furthermore, PARP activity was not inhibited by temozolomide treatment and this newly validated pharmacodynamic assay is therefore suitable for use in a proof-of-principle phase I trial a PARP-1 inhibitor in combination with temozolomide.
CitationTemozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. 2005, 11 (9):3402-9 Clin. Cancer Res.
JournalClinical Cancer Research
- O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
- Authors: Middleton MR, Lee SM, Arance A, Wood M, Thatcher N, Margison GP
- Issue date: 2000 Nov 1
- Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
- Authors: Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL
- Issue date: 2001 Aug
- New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
- Authors: Spiro T, Liu L, Gerson S
- Issue date: 2000 Jul-Sep
- Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
- Authors: Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G
- Issue date: 2002 Oct
- A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
- Authors: Senhaji Mouhri Z, Goodfellow E, Jean-Claude B
- Issue date: 2017 Aug 11